Inhibikase TherapeuticsIKT +1.60%33 Current Ratio is 30.14 as of Mar. 2026, which is 299% above its 10-year median of 7.56. GuruFocus rates IKT with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,413 Biotechnology companies, Inhibikase Therapeutics ranks better than 96.53% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Inhibikase Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 30.14.
Inhibikase Therapeutics has a current ratio of 30.14. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Inhibikase Therapeutics's Current Ratio or its related term are showing as below:
IKT'
s Current Ratio Range Over the Past 10 Years
Min: 0.01 Med: 7.56 Max: 30.14
Current: 30.14
During the past 8 years, Inhibikase Therapeutics's highest Current Ratio was 30.14. The lowest was 0.01. And the median was 7.56.
IKT's Current Ratio is ranked better than 96.53% of 1413
companies
in the Biotechnology industry
Industry Median: 3.89
vs IKT: 30.14
Inhibikase Therapeutics (NAS:IKT) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Inhibikase Therapeutics Current Ratio Related Terms
Inhibikase Therapeutics Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Inhibikase Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibikase Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Inhibikase Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibikase Therapeutics (IKT) has a Current Ratio of 30.14 as of Mar. 2026. This is 299% above median its historical median of 7.56. Over the past decade, Inhibikase Therapeutics' Current Ratio has ranged from 0.01 to 30.14. According to the industry distribution chart, Inhibikase Therapeutics ranks #49 out of 1413 companies in the Biotechnology industry, placing it in the top 3.5%.
Is Inhibikase Therapeutics' Current Ratio too high?
Inhibikase Therapeutics' current Current Ratio of 30.14 is 299% above median its 10-year median of 7.56. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 30.14. The Biotechnology industry median Current Ratio is 3.89. Inhibikase Therapeutics' value of 30.14 is 674.8% above this industry median. Based on the distribution chart, Inhibikase Therapeutics ranks #49 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Inhibikase Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' Current Ratio compare to NKTX and CAMP?
According to the Biotechnology industry distribution chart, Inhibikase Therapeutics ranks #49 out of 1413 companies for Current Ratio. This places Inhibikase Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Inhibikase Therapeutics' value of 30.14 is 674.8% above this benchmark. Historically, Inhibikase Therapeutics' own Current Ratio has ranged from 0.01 to 30.14 over the past decade. While the company's 10-year median is 7.56 vs. the industry median of 3.89, Inhibikase Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inhibikase Therapeutics's current Current Ratio of 30.14 is 674.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inhibikase Therapeutics's current Current Ratio is 30.14, which is 299% above median its own 10-year median of 7.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current Current Ratio of 30.14. The current Current Ratio is 30.14, which is 299% above median its 10-year median of 7.56 and 674.8% above the Biotechnology industry median of 3.89. Inhibikase Therapeutics' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current Current Ratio is 30.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
33GF Score
Get the complete analysis for IKT
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IKT has been successfully added to your 
